March 8, 2018 – Servier, Pfizer Inc. (NYSE: PFE) and Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), today announced that results from the two phase 1 trials with UCART19, the allogeneic anti-CD19 CAR T-cell product being developed by Servier and Pfizer, will be presented during the European society for Blood and Marrow Transplantation (EBMT) Annual Meeting…
House Republicans failed Tuesday evening to pass a “right-to-try” bill that would give terminally ill patients access to experimental drugs without FDA authorization after failing to muster enough votes to approve it through an expedited process. The 259-140 vote fell short of the necessary two-thirds support from the House chamber. The failed vote is a…
BrainStorm Cell Therapeutics, Inc. (NASDAQ:BCLI) has enrolled the first patients in the Phase 3 clinical trial of NurOwn® (NCT03280056) for the treatment of amyotrophic lateral sclerosis (ALS). The trial is taking place at six leading U.S. Medical centers. It is a randomized, double blind, placebo controlled, multi-dose trial that is expected to enroll approximately 200…
One day, you may be able to stop flu viruses in your body in just one day with just one pill. Based on an announcement yesterday, that day may be someday very soon in May in Japan. On Friday, Japanese pharmaceutical company Shionogi announced that the flu medication that they have developed, Xofluza, otherwise known…
New York, NY — February 15, 2018 — Transparency Life Sciences (TLS), a pioneer in digital drug development clinical services, today announced completion of a $5.0 million Series A financing led by venture investor New Ventures III. Existing private investors also participated. TLS will use the new financing to expand the company’s technology platform and…
Was Once Thought to Be ‘Uncontrollable’ Bleeding The new technology is hailed by its inventors as a life-saving bandage that can succeed where conventional treatment procedures might fail to stop a deadly hemorrhage. More at: https://www.haaretz.com/israel-news/new-israeli-bandage-can-stop-uncontrollable-bleeding-1.5402251
The Angiopoietin 1 Receptor Market 2018 Research Report studies an absolute and exhaustive study on Angiopoietin 1 Receptor industry volume, Market Share, Industry Trends, Angiopoietin 1 Receptor Growth appearances, the wide range of applications, Utilization ratio, Supply including demand analysis, production capacity, Price during the Forecast period from 2018 to 2023. High Use of Angiopoietin 1 Receptor…
New York City is doubling down on its long-discussed, never-realized dream of building a biotech hub to rival South San Francisco and Boston. The latest iteration of the dream comes backed by a $500 million financing package and a goal to quadruple the amount of R&D space in the city. City officials sketched out the…
By end of 2019, Regeneron plans to sequence the exomes of all 500,000 people within the UK Biobank resource, all with associated health records, creating an unprecedented resource linking human genetic variations to human biology and disease AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen and Pfizer will join Regeneron to co-fund one of the industry’s most ambitious…
Pfizer Inc. on Saturday said it would stop trying to discover new drugs for Alzheimer’s disease and Parkinson’s disease, abandoning costly but futile efforts to find effective treatments for the disorders. More at: https://www.wsj.com/articles/pfizer-ends-hunt-for-drugs-to-treat-alzheimers-and-parkinsons-1515267654
